<DOC>
	<DOCNO>NCT01774968</DOCNO>
	<brief_summary>The main purpose study compare effectiveness Human Regular U-500 Insulin three time day versus twice day .</brief_summary>
	<brief_title>Study Human Regular U-500 Insulin Adult Participants With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Major Have type 2 diabetes mellitus ( World Health Organization [ WHO ] Classification Diabetes ) Have body mass index ( BMI ) ≥25 kilogram per square meter ( kg/m^2 ) Have Glycated Hemoglobin A1c ( HbA1c ) ≥7.5 % ≤12.0 % , measure central laboratory entry Current U100 insulin/analogue user &gt; 200 ≤600 unit per day ≥3 month study entry reconfirm randomization Have history stable body weight least 3 month prior study entry Concomitant medication may include metformin ( MET ) , dipeptidyl peptidase4 ( DPP4 ) inhibitor approve use insulin time study entry ( example , sitagliptin , saxagliptin , linagliptin ) , pioglitazone , and/or sulfonylurea ( SUs ) /glinides ( repaglinide nateglinide ) . Participant 's oral antihyperglycemic drug ( OAD ) dose ( ) must stable ≥3 month Major Have type 1 diabetes mellitus type diabetes mellitus apart type 2 diabetes mellitus Have obvious clinical sign symptom liver disease , acute chronic hepatitis , alanine aminotransferase aspartate aminotransferase level ≥3 time upper limit reference range Have chronic kidney disease stage 4 high history renal transplantation Have history 1 episode severe hypoglycemia within 6 month prior study entry Have receive insulin continuous subcutaneous insulin infusion 3 month prior study entry Have receive U500R 3 month prior study entry Have blood transfusion severe blood loss within 3 month prior study entry know hemoglobinopathy , hemolytic anemia , sickle cell anemia Are take chronic systemic glucocorticoid therapy receive therapy within 4 week immediately prior study entry Have irregular sleep/wake cycle Have use rosiglitazone , twicedaily glucagonlike peptide1 ( GLP1 ) receptor agent , pramlintide , injectable oral antihyperglycemic therapy list inclusion criterion 3 month prior study entry . Participants may use onceweekly GLP1 receptor agent 4 month prior study entry Have use weight loss drug 3 month prior study entry Have history bariatric surgery Have history malignancy basal cell squamous cell skin cancer Have New York Heart Association ( NYHA ) Class III IV per NYHA Cardiac Disease Functional Classification Are breastfeed pregnant , intend become pregnant course study , sexually active woman childbearing potential actively practice birth control method determine investigator medically acceptable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>